<DOC>
	<DOCNO>NCT01439321</DOCNO>
	<brief_summary>Chronic immune thrombocytopenic purpura ( ITP ) characterize low platelet count risk severe bleed complication . The two recently introduce TPO-RA drug , namely , eltrombopag romiplostim , show efficacious sustain response continuous administration . Both drug indicate treatment thrombocytopia patient chronic ITP insufficient response corticosteroid , immunoglobulin , splenectomy . While trial address important clinical question intend evaluate happens real-world setting actual patient live daily life . The purpose health outcome study understand two TPO receptor agonist ( TPO-RA ) currently available US use clinical practice use impact chronic ITP patient ' daily life . The study hypothesis patient switch eltrombopag report well health-related quality life switch romiplostim . This study utilize hybrid design retrospective chart review study cross-sectional patient survey . A customized Patient Case Report Form ( CRF ) use retrospectively collect clinical data patient medical chart primary cohort consist patient switch ITP medication eltrombopag romiplostim . A cross-sectional survey employ collect patient report outcome ( PRO ) data , include health-related quality life treatment satisfaction , use compository questionnaire . Analyses cross-sectional survey data retrospective medical chart review data patient switch either eltrombopag romiplostim prior primary therapy conduct .</brief_summary>
	<brief_title>Outcomes Comparison Chronic Immune Thrombocytopenic Purpura ( ITP ) Patients Switched Eltrombopag Romiplostim</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Inclusion criterion Adults 18 year old diagnose chronic ITP Switched eltrombopag romiplostim minimum 4 week prior index date Received corticosteroid , rituximab , one TPOreceptor agonist prior primary therapy switch eltrombopag romiplostim Medical history must available chronic ITP diagnosis recent office visit Patients complete selfadministered questionnaire patient whose medical chart review Exclusion criterion Age le 18 year old</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>treatment satisfaction</keyword>
	<keyword>romiplostim</keyword>
	<keyword>eltrombopag</keyword>
	<keyword>chronic immune thrombocytopenic pupura</keyword>
</DOC>